Invention Application
US20110189789A1 NOVEL TARGET PROTEIN OF ANTICANCER AGENT AND NOVEL ANTICANCER AGENT (SPNAL) CORRESPONDING THERETO
审中-公开
新药抗体药剂和新型抗感染药物（SPNAL）相关药物的新目标蛋白
- Patent Title: NOVEL TARGET PROTEIN OF ANTICANCER AGENT AND NOVEL ANTICANCER AGENT (SPNAL) CORRESPONDING THERETO
- Patent Title (中): 新药抗体药剂和新型抗感染药物（SPNAL）相关药物的新目标蛋白
-
Application No.: US12632905Application Date: 2009-12-08
-
Publication No.: US20110189789A1Publication Date: 2011-08-04
- Inventor: Akito Tanaka , Akira Yamazaki , Takeshi Tsutsumi , Tomohiro Terada , Masayuki Haramura
- Applicant: Akito Tanaka , Akira Yamazaki , Takeshi Tsutsumi , Tomohiro Terada , Masayuki Haramura
- Applicant Address: JP TOKYO
- Assignee: REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD.
- Current Assignee: REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD.
- Current Assignee Address: JP TOKYO
- Priority: JP2003-401132 20031201
- Main IPC: G01N33/53
- IPC: G01N33/53
Abstract:
The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound that specifically binds to KSRP or a functional fragment thereof, and a screening method for the compound. KSRP is a novel target protein for anticancer agents; a compound capable of regulating the expression and activity of such a protein and a pharmaceutical composition containing it are highly useful for proliferative diseases, particularly as anticancer agents. By providing the novel target protein, the mechanism behind the anticancer effect that has conventionally been unexplainable can be elucidated.
Information query
IPC分类:
